NCT05567770View on ClinicalTrials.gov

ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2030

Conditions
Prostate Cancer Metastatic
Interventions
DRUG

Actinium-J591

Cohort 1 with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy

RADIATION

Stereotactic Body Radiation Therapy

Cohort 1 patients with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy

DRUG

Androgen Deprivation Therapy

Cohort 2 patient with Polymetastatic disease will receive Actinium-J591 and Androgen Deprivation therapy (ADT)

Sponsors
All Listed Sponsors
collaborator

Convergent Therapeutics, Inc.

UNKNOWN

lead

Weill Medical College of Cornell University

OTHER

NCT05567770 - ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer | Biotech Hunter | Biotech Hunter